Among these, oncolytic adenoviruses (OAds) engineered to locally express SIRPα-Fc have shown efficacy in preclinical tumor models by reprogramming TAMs and DCs toward a pro-inflammatory, antigen-presenting phenotype, leading to enhanced CD8+ T cell responses and synergy with PD-1 blockade [330]. Here, SIRPA is linked to neoplasm.